CA2904166C - Formulations with reduced oxidation - Google Patents

Formulations with reduced oxidation Download PDF

Info

Publication number
CA2904166C
CA2904166C CA2904166A CA2904166A CA2904166C CA 2904166 C CA2904166 C CA 2904166C CA 2904166 A CA2904166 A CA 2904166A CA 2904166 A CA2904166 A CA 2904166A CA 2904166 C CA2904166 C CA 2904166C
Authority
CA
Canada
Prior art keywords
formulations
protein
methods
oxidation
reduced oxidation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2904166A
Other languages
French (fr)
Other versions
CA2904166A1 (en
Inventor
Sreedhara Alavattam
Mary MALLANEY
Parbir GREWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA3113172A priority Critical patent/CA3113172A1/en
Publication of CA2904166A1 publication Critical patent/CA2904166A1/en
Application granted granted Critical
Publication of CA2904166C publication Critical patent/CA2904166C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Lubricants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.
CA2904166A 2013-03-13 2014-03-13 Formulations with reduced oxidation Active CA2904166C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3113172A CA3113172A1 (en) 2013-03-13 2014-03-13 Screen for compound that prevents protein oxidation based on comparison with l-tryptophan

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780845P 2013-03-13 2013-03-13
US61/780,845 2013-03-13
US201361909813P 2013-11-27 2013-11-27
US61/909,813 2013-11-27
PCT/US2014/026841 WO2014160495A1 (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3113172A Division CA3113172A1 (en) 2013-03-13 2014-03-13 Screen for compound that prevents protein oxidation based on comparison with l-tryptophan

Publications (2)

Publication Number Publication Date
CA2904166A1 CA2904166A1 (en) 2014-10-02
CA2904166C true CA2904166C (en) 2021-05-18

Family

ID=51625442

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2904166A Active CA2904166C (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation
CA3113172A Abandoned CA3113172A1 (en) 2013-03-13 2014-03-13 Screen for compound that prevents protein oxidation based on comparison with l-tryptophan

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3113172A Abandoned CA3113172A1 (en) 2013-03-13 2014-03-13 Screen for compound that prevents protein oxidation based on comparison with l-tryptophan

Country Status (25)

Country Link
EP (1) EP2968466B1 (en)
JP (3) JP6389236B2 (en)
KR (1) KR102237885B1 (en)
CN (2) CN104968362B (en)
AU (3) AU2014243700B2 (en)
BR (1) BR112015022484A2 (en)
CA (2) CA2904166C (en)
DK (1) DK2968466T3 (en)
ES (1) ES2688895T3 (en)
HK (1) HK1211219A1 (en)
HR (1) HRP20181504T1 (en)
HU (1) HUE039948T2 (en)
IL (2) IL269947B (en)
LT (1) LT2968466T (en)
MX (2) MX369671B (en)
MY (1) MY174679A (en)
NZ (1) NZ711566A (en)
PL (1) PL2968466T3 (en)
PT (1) PT2968466T (en)
RS (1) RS57813B1 (en)
RU (1) RU2707092C2 (en)
SG (2) SG10201705525VA (en)
SI (1) SI2968466T1 (en)
WO (1) WO2014160495A1 (en)
ZA (2) ZA201506876B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
WO2014160497A1 (en) * 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
KR20230074823A (en) 2016-06-27 2023-05-31 모르포시스 아게 Anti-cd19 antibody formulations
CN111194233A (en) * 2017-10-13 2020-05-22 株式会社田村特科 Method for treating harmful substance and ozone generator
AR115925A1 (en) 2018-08-08 2021-03-10 Genentech Inc USE OF TRYPTOPHAN AND L-METHIONINE DERIVATIVES FOR PROTEIN FORMULATION

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methods for the production of humanized antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1386660B1 (en) 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolation of immunoglobulins
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy PROCESS FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2001236005A1 (en) 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP1367998A4 (en) * 2000-09-15 2004-03-17 Scripps Research Inst Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
EP1463522A4 (en) 2001-05-16 2005-04-13 Einstein Coll Med Human antipneumococcal antibodies from non-human animals
ATE531390T1 (en) 2001-08-23 2011-11-15 Genmab As INTERLEUKIN-15 (IL-15) SPECIFIC HUMAN ANTIBODIES
US7682608B2 (en) * 2001-08-29 2010-03-23 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20060258841A1 (en) 2003-01-17 2006-11-16 Josef Michl Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004270103B2 (en) 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
WO2006001832A2 (en) * 2003-12-18 2006-01-05 The Scripps Research Institute Selective incorporation of 5-hyroxytryptophan into proteins in mammalian cells
EP1986674A4 (en) * 2006-02-13 2009-11-11 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
CN101616685B (en) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 Unstructured recombinant polymers and uses thereof
JP2007319124A (en) * 2006-06-02 2007-12-13 Nippon Tablet Kk Health food
TWI440456B (en) * 2007-01-16 2014-06-11 Novel composition for treating metabolic syndrome
SG10201608068SA (en) * 2008-04-01 2016-11-29 Antipodean Pharmaceuticals Inc Compositions And Methods For Skin Care
ES2616231T3 (en) * 2008-08-21 2017-06-12 Immunogenics Llc Formulation for oral protein administration
CN103599541A (en) * 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 Compositions and methods for the prevention of oxidative degradation of proteins
MX2011003013A (en) * 2008-09-19 2011-04-11 Pfizer Stable liquid antibody formulation.
KR101924653B1 (en) * 2010-06-24 2018-12-03 제넨테크, 인크. Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations
RU2447448C1 (en) * 2010-08-30 2012-04-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" Method for stabilising antibodies in aqueous solutions
WO2012170883A1 (en) * 2011-06-09 2012-12-13 Discovery Pharma Consulting, Llc Antihistamines combined with dietary supplements for improved health
US9321848B2 (en) * 2011-06-28 2016-04-26 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide

Also Published As

Publication number Publication date
ZA201906057B (en) 2022-04-28
IL240933A0 (en) 2015-11-30
MX369671B (en) 2019-11-15
BR112015022484A2 (en) 2017-07-18
HK1211219A1 (en) 2016-05-20
SG11201507043SA (en) 2015-10-29
KR20150130397A (en) 2015-11-23
NZ711566A (en) 2020-06-26
JP2018150317A (en) 2018-09-27
AU2014243700B2 (en) 2019-01-24
IL269947A (en) 2019-12-31
ES2688895T3 (en) 2018-11-07
WO2014160495A1 (en) 2014-10-02
SG10201705525VA (en) 2017-08-30
EP2968466A1 (en) 2016-01-20
SI2968466T1 (en) 2018-10-30
EP2968466B1 (en) 2018-07-25
JP2016520521A (en) 2016-07-14
KR102237885B1 (en) 2021-04-07
PL2968466T3 (en) 2018-11-30
MX2015011432A (en) 2016-04-27
ZA201506876B (en) 2019-12-18
MX2019013560A (en) 2020-01-20
HUE039948T2 (en) 2019-02-28
PT2968466T (en) 2018-10-22
RU2015143548A (en) 2017-04-20
AU2019202464B2 (en) 2020-12-10
RS57813B1 (en) 2018-12-31
CN110075293A (en) 2019-08-02
MY174679A (en) 2020-05-06
LT2968466T (en) 2018-10-10
IL269947B (en) 2022-08-01
AU2021201366A1 (en) 2021-03-18
AU2019202464A1 (en) 2019-05-02
CA2904166A1 (en) 2014-10-02
AU2014243700A1 (en) 2015-10-08
RU2707092C2 (en) 2019-11-22
JP2020164531A (en) 2020-10-08
EP2968466A4 (en) 2016-10-26
CN104968362A (en) 2015-10-07
IL240933B (en) 2019-10-31
JP6389236B2 (en) 2018-09-12
HRP20181504T1 (en) 2018-11-02
NZ751543A (en) 2020-09-25
DK2968466T3 (en) 2018-10-22
CN104968362B (en) 2018-12-14
CA3113172A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
EP3419676A4 (en) Antimicrobial compositions and uses thereof
EP3258962A4 (en) Mixed allergen compositions and methods for using the same
WO2015038796A3 (en) Secretion of heme-containing polypeptides
WO2015120062A3 (en) Therapeutic compounds and compositions
EP3385255A4 (en) Fungicidal compound, fungicide composition and preparation and use thereof
WO2015051030A8 (en) Stabilized polypeptides and uses thereof
CA2904166C (en) Formulations with reduced oxidation
EP3494119A4 (en) Compounds and compositions and uses thereof
EP3758495A4 (en) Nanoparticle compositions
EP3261437A4 (en) Fungicidal compounds and compositions
EP3722395A4 (en) Friction-controlling compound, and friction-controlling composition containing said friction-controlling compound
EP3074000A4 (en) Suspension compositions of physiologically active phenolic compounds&methods of making and using the same
EP3556343A4 (en) Oil-in-water type composition
IL262020B (en) Griseofulvin compound, compositions containing same and uses thereof
EP3421038A4 (en) Naphthyridine compound, pharmaceutical composition and use thereof
EP3527225A4 (en) Composition containing anti-robo4 antibody and other agents
AR095398A1 (en) FORMULATIONS WITH REDUCED OXIDATION
EP3520614A4 (en) Nematode control composition comprising grammicin compound as active ingredient and use thereof
ZA201902996B (en) Stable solid composition based on an aromatic compound and uses thereof
EP3392261A4 (en) Steroidal compound, composition containing the same and use thereof
EP3758490A4 (en) Nanoparticle compositions
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP3153492A4 (en) Novel compound and fragrance composition containing same
EP3716766A4 (en) Benzoxaborole compounds and formulations thereof
MX370416B (en) Formulations with reduced oxidation.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190312